Development of new therapeutics for Alzheimer´s disease
|Coordinator||Göteborgs Universitet - Institutionen för neurovetenskap och fysiologi|
|Funding from Vinnova||SEK 1 766 530|
|Project duration||July 2015 - June 2018|
Purpose and goal
The lack of treatments of age-related disorders, such as Alzheimer´s disease (AD), is a global challenge for our society. This project, which is a collaboration between the research group of associate professor Petronella Kettunen at University of Gothenburg (including the newly formed Centre for Cognitive Medicine, CCM) and biotech/pharmaceutical companies in the Oxford region, aims at combining unique methods and hypotheses to develop novel diagnostics and therapeutics for AD.
Expected results and effects
The overall goal of this project is to increase the understanding of AD to allow for the development of future AD diagnostics and therapies based on compounds that modulate specific pathways that affects neurodegeneration in AD. In addition, this collaboration will also mean new connections between University of Gothenburg and the Oxford region and enhance the competitiveness of academia and the healthcare and private sectors in Sweden.
Planned approach and implementation
The project will include work in all phases of the drug development process, from preclinical development to planning of future clinical trials. The complementary methods, strengths and expertise of the partners will contribute to a successful long-term collaboration. During the project period, Dr Kettunen will also acquire highly relevant skills in innovation,leadership and project management.